Experimental virus therapy takes on advanced tumors in early trial
NCT ID NCT05165433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment called NG-350A, a virus designed to target tumors and boost immune activity, combined with the immunotherapy drug pembrolizumab. Fourteen people with advanced epithelial cancers that had stopped responding to standard treatments received the combination. The main goal was to check safety and side effects, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NG-350A (a virus that targets tumors and activates immune cells) plus pembrolizumab (an immunotherapy drug)
What this could lead to
If this combination proves safe and shows signs of shrinking tumors, it could point toward a new treatment option for advanced epithelial cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 14 people, so it is designed mainly to check safety, not effectiveness. The approach may not work in larger studies, and side effects from the virus or immunotherapy could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt-Advent Health Clinical Research Unit
Celebration, Florida, 34747, United States
-
Perelman Center of Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Providence Medical Foundation
Santa Monica, California, 90404, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Lancashire, L7 8YA, United Kingdom
-
UCLA
Santa Monica, California, 90404, United States